昆仙胶囊治疗原发性IgA肾病疗效观察  

Effect of Kunxian capsule in the treatment of primary IgA nephropathy

作　　者：马媛媛 姬萌 郭醉爽 马东红[1] 许清玉[1] 尚瑞华 侯玉龙[1] 郭明好[1] MA Yuanyuan;JI Meng;GUO Zuishuang;MA Donghong;XU Qingyu;SHANG Ruihua;HOU Yulong;GUO Minghao(The Nephrology Hospital,the First Affiliated Hospital of Xinxiang Medical University,Weihui 453100,Henan Province,China;Department of Nephrology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,Henan Province,China)

机构地区：[1]新乡医学院第一附属医院肾脏病医院,河南卫辉453100 [2]郑州大学第一附属医院肾内科,河南郑州450000

出　　处：《新乡医学院学报》2021年第10期961-965,共5页Journal of Xinxiang Medical University

基　　金：北京康盟慈善基金会医学科研发展基金项目(编号:WS666A)。

摘　　要：目的探讨昆仙胶囊治疗原发性IgA肾病的疗效及安全性。方法选择2018年10月至2020年4月新乡医学院第一附院医院诊治的63例原发性IgA肾病患者为研究对象,将患者按治疗方法分为泼尼松组(32例)和昆仙胶囊组(31例)。泼尼松组患者在常规治疗基础上给予醋酸泼尼松片0.5 mg·kg^(-1)·d^(-1)口服,连续治疗12周;昆仙胶囊组患者在常规治疗基础上给予昆仙胶囊口服,每次0.6 g,每日3次,连续治疗12周。比较治疗前、治疗4周、治疗12周时2组患者的24 h尿蛋白定量、血肌酐、血尿酸、血尿素、血清白蛋白及血红蛋白等指标变化,比较2组患者治疗期间不良反应发生情况。结果治疗4周时,2组患者24 h尿蛋白显著低于治疗前(P<0.05);治疗12周时,2组患者24 h尿蛋白显著低于治疗前和治疗4周时(P<0.05);治疗前和治疗4周时,昆仙胶囊组与泼尼松组患者24 h尿蛋白比较差异无统计学意义(P>0.05);治疗12周时,昆仙胶囊组患者24 h尿蛋白显著低于泼尼松组(P<0.05)。2组患者治疗12周时的尿蛋白下降率显著高于治疗4周时(P<0.05);治疗4、12周时,昆仙胶囊组患者尿蛋白下降率显著高于泼尼松组(P<0.05)。2组患者不同时间点组内、组间血肌酐水平比较差异均无统计学意义(P>0.05)。2组患者治疗前血清白蛋白比较差异无统计学意义(P>0.05);治疗4、12周时,泼尼松组患者血清白蛋白显著高于治疗前及昆仙胶囊组(P<0.05)。昆仙胶囊组患者不同时间点血清白蛋白水平比较差异无统计学意义(P>0.05)。2组患者血红蛋白、血尿酸及血尿素氮水平治疗前后组内、组间比较差异均无统计学意义(P>0.05)。治疗12周后,昆仙胶囊组患者总缓解率为100.00%(31/31),泼尼松组患者总缓解率为78.13%(25/32);昆仙胶囊组患者总缓解率显著高于泼尼松组(P<0.05)。昆仙胶囊组患者不良反应发生率为3.23%(1/31),泼尼松组不良反应发生率为28.13%(9/32);昆仙胶囊组患Objective To investigate the efficacy and safety of Kunxian capsule in the treatment of primary IgA nephropathy.Methods Sixty-three patients with primary IgA nephropathy admitted to the First Affiliated Hospital of Xinxiang Medical University from October 2018 to April 2020 were selected as research subjects,and they were divided into the prednisone group(n=32)and Kunxian capsule group(n=31)according treatment method.The patients in the prednisone group were given prednisone acetate tablets 0.5 mg·kg^(-1)·d^(-1) orally on the basis of routine treatment for 12 weeks;on the basis of routine treatment,the patients in the Kunxian capsule group were given Kunxian capsule orally,0.6 g each time,3 times per day for 12 weeks.The changes of 24-hour urinary protein,blood creatinine,blood uric acid,blood urea,serum albumin and hemoglobin of patients between the two groups before treatment,4 and 12 weeks of treatment were compared,and the incidence of adverse reactions of patients during treatment between the two groups was compared.Results At 4 weeks of treatment,the 24-hours urinary protein of patients in the two groups was significantly lower than that before treatment(P<0.05);at 12 weeks of treatment,the 24-hours urinary protein of patients in the two groups was significantly lower than that before treatment and 4 weeks of treatment(P<0.05).There was no significant difference in 24-hours urinary protein of patients between the two groups before treatment and 4 weeks of treatment(P>0.05),the 24-hours urinary protein of patients in the Kunxian capsule group was significantly lower than that in the prednisone group at 12 weeks of treatment(P<0.05).The rate of urinary protein decrease of patients in the two groups at 12 weeks of treatment was significantly higher than that at 4 weeks of treatment(P<0.05),and the rate of urinary protein decrease of patients in the Kunxian capsule group was significantly higher than that in prednisone group at 4 and 12 weeks of treatment(P<0.05).There was no significant difference in serum c

关 键 词：IGA肾病 昆仙胶囊 泼尼松 尿蛋白定量 

分 类 号：R692.31[医药卫生—泌尿科学]